Nifty 50 index rallies, pharmaceutical stocks in focus
In recent trading news, the NSE Nifty index rose by 61.3 points to 19,584.85 on Friday, September 29, 2023. This increase was largely driven by buying in frontline blue chip stocks. Among...
Neutral
or
Glenmark Pharma News & Analysis
-
-
Nomura/Instinet downgrades Glenmark Pharma to 'neutral' with a price target of INR841.00
An analyst from Nomura/Instinet downgraded Glenmark Pharma (NS: GLEN) from 'buy' to 'neutral' with a price target of INR841.00 from a prior price target of %currency%%price%. Prior to this...
-
Glenmark closes 3% lower post API arm sale deal
According to analysts, the sale of Glenmark Life could impact the profitability of Glenmark Pharma in FY25 but lower interest payments could offset the impact. ICICI Securities said the...
-
Glenmark Pharma sale of Glenmark Life Sciences: What it means for investors?
Major overhang cleared, but dilution and outlook need redressal
-
Glenmark Pharma shares drop following major divestment of subsidiary
Shares of Mumbai-based Glenmark Pharmaceuticals (NS:GLEN) fell 4.5% to Rs 790.25 on the National Stock Exchange (NSE) in early trade on Friday, following the company's announcement of a...
-
Nuvama maintains Glenmark Pharma at 'hold' with a price target of INR830.00
An analyst from Nuvama maintained Glenmark Pharma (NS: GLEN) at 'hold' with a price target of INR830.00. Prior to this rating, Glenmark Pharma had 4 buy ratings, 7 hold ratings, and 4 sell...
-
-
Glenmark Pharma, Glenmark Life shares in news on Nirma deal. What analysts say
Glenmark Pharma, Glenmark Life: The fresh move, analysts said, may help Glenmark Pharma pare debt and increase its emphasis on branded or innovative products, they said.
-
Stocks in news: Glenmark Pharma, Infosys, JSW Steel, ICICI Bank, Vedanta and more
Stocks to watch out for today: Glenmark Pharmaceuticals, ICICI Bank, Vedanta, Zuari Industries, InterGlobe Aviation, Tech Mahindra, Infosys, JSW Steel and more
-
-
Glenmark Pharma to sell 75% stake in life sciences unit to Nirma for Rs 5,651 cr
New Delhi, Sep 21 (IANS) Glenmark Pharmaceuticals Ltd (GPL) has agreed to divest 75 per cent stake in its subsidiary Glenmark Life Sciences (NS:GLEM) to Nirma Limited at a price of Rs 615...
-
Glenmark Pharma to sell 75% stake in Glenmark Life Sciences to Nirma for Rs 5,652 cr
Glenmark Pharma will own 7.84% in GLS after the divestment; pursuant to the transaction, Nirma Limited will make a mandatory open offer to all public shareholders of GLS
-
Glenmark Pharma, KSB, 4 other small cap stocks hit 52-week high on Thursday
Small-cap stocks stole the spotlight today on September 21, 2023, as several companies achieved significant milestones, hitting new 52-week highs.
-
Infosys, Glenmark Pharma, L&T: Here's what Mileen Vasudeo of Arihant Capital says on these 3 stocks
Top stock picks for today: Mileen Vasudeo also recommended HG Infra Engineering Ltd. For HG Infra, keep a stop loss at Rs 946 and the price target would be Rs 1,060 to Rs 1,100 in a couple...
-
HSBC maintains Glenmark Pharma at 'hold' with a price target of INR725.00
An analyst from HSBC maintained Glenmark Pharma (NS: GLEN) at 'hold' with a price target of INR725.00 from a prior price target of %currency%%price%. Prior to this rating, Glenmark Pharma...
-
US fines Teva, Glenmark $255 mn over drug price-fixing charges
Washington, Aug 22 (IANS) The US has fined top drug-making companies Teva Pharmaceuticals and Glenmark Pharmaceuticals (NS:GLEN) a total of $255 million for price-fixing fixing...
-
Glenmark Pharma: Is the rally in the stock sustainable?
Asset monetisation, plant clearance, and earnings growth baked into estimates and valuations
-
ChrysCapital still in race to buy controlling stake in Glenmark Life Sciences
Private equity firm ChrysCapital remains firmly in the running to buy Glenmark Pharma's stake in Glenmark Life Sciences (GLS) with rival bidder Nirma. Along with Nirma and ChrysCapital,...
-
ONGC, Apollo Hospitals, HAL, Nykaa Among 227 Cos to Release Q1 Today
By Malvika Gurung Investing.com -- A total of a whopping 227 listed companies are scheduled to release their financial earnings for the quarter ended June 30, 2023, on Friday, August 11,...
-
Lupin, Glenmark Pharma, 7 BSE Healthcare stocks which hit 52-week high on Wednesday
The data was sourced from BSE at 2.50 pm, and the updates from the real-time data could come with a lag. The below data also pertains only to the time at which it was taken.
-
HSBC maintains Glenmark Pharma at 'hold' with a price target of INR620.00
An analyst from HSBC maintained Glenmark Pharma (NS: GLEN) at 'hold' with a price target of INR620.00 from a prior price target of %currency%%price%. Prior to this rating, Glenmark Pharma...
-
Goldman Sachs maintains Glenmark Pharma at 'neutral' with a price target of INR570.00
An analyst from Goldman Sachs maintained Glenmark Pharma (NS: GLEN) at 'neutral' with a price target of INR570.00 from a prior price target of %currency%%price%. Prior to this rating,...
-
HSBC maintains Glenmark Pharma at 'hold' with a price target of INR515.00
An analyst from HSBC maintained Glenmark Pharma (NS: GLEN) at 'hold' with a price target of INR515.00 from a prior price target of %currency%%price%. Prior to this rating, Glenmark Pharma...
-
Major Companies Set to Release Q4 Earnings This Week
By Malvika Gurung Investing.com -- The week starting on May 14, 2023, will be lined with more than 500 companies set to release earnings results for the quarter ended March 31, 2023. This...
-
3 Stocks that touched a fresh 52 week high today; Check the details
Domestic benchmark indices were trading sideways on Tuesday. The Sensex reclaimed the 60,000-level mark after opening in the negative territory, and was at 60,179 points, up 0.21% at 11:50...
-
BioAsia 2023 to focus on opportunities in life science post-Covid
Hyderabad, Jan 10 (IANS) BioAsia 2023, Asia's largest life-sciences and healthcare forum, scheduled to be held next month, will discuss the learnings, challenges and opportunities in life...
-
Lupin Zooms Over 4% in Weak Market, USFDA Approves ANDA For Briviact Tablets
By Malvika Gurung Investing.com -- Shares of the pharmaceutical major Lupin (NS:LUPN) surged 4.22% to Rs 756.6 apiece at the time of writing, defying the market mood as headline indices...
-
Mkt-Mover Alert: Key Q2 Results Ahead- Tata Motors, LIC, Coal India, BPCL & More
By Malvika Gurung Investing.com -- The domestic market made a higher closing on Friday, snapping two sessions of losses, with the equity benchmark indices ending the week with up to 2%...
-
In Focus on Nov 1: Tata, Adani Group Stocks, 5 Mega-Cap Stocks & More
By Malvika Gurung Investing.com -- Larsen & Toubro (NS:LART): The conglomerate major’s consolidated PAT rose 22.5% YoY to Rs 2,229 crore in Q2 and consolidated revenue surged 23% to Rs...
-
Stocks Under Focus: Hero Moto, Dabur, Tata Steel, Gland Pharma & More
By Malvika Gurung Investing.com -- Hero MotoCorp (NS:HROM): The world’s leading two-wheeler manufacturer has partnered with Terrafirma Motors to assemble and distribute its vehicles amid...
-
Glenmark Pharma earnings beat, Revenue misses in Q2
Investing.com - Glenmark Pharma (NS:GLEN) reported on Friday second quarter {{erl-39480||earnings that beat analysts' forecasts and revenue that fell short of expectations. Glenmark Pharma...
-
Stocks in Focus on Dec 15: SBI, ITC, Vedanta & More
By Malvika Gurung Investing.com -- ITC Ltd (NS:ITC): The cigarette-to-hotels conglomerate in its analyst meet on Dec 14, did not give any for demerger and listing of its businesses but did...
-
Should You Subscribe to Glenmark Life Sciences IPO?
By Aditya Raghunath Investing.com -- Glenmark Life Sciences opens its IPO today. The company is an API (active pharmaceutical ingredient) subsidiary of Glenmark Pharma (NS:GLEN) that is...
-
Top 5 Midcap Stocks that Mutual Funds Bought and Sold in April 2021
By Aditya Raghunath Investing.com -- Mutual fund buying and selling data in April in the midcap space threw up a couple of surprises. Like funds bought a lot of Vodafone Idea stock. In fact,...
-
3 Mid and Small-cap Stocks Where Ashish Dhawan Increased Stake in March Quarter
By Aditya Raghunath Investing.com -- Mid-cap and small-cap companies have been on a roll in stock markets in 2021. The NIFTY Midcap 100 Index has risen 25% from December 2020 while the S&P...
-
BRIEF-Glenmark Pharma Launches Ryaltris-AZ Nasal Spray In India
May 3 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS :* LAUNCHES RYALTRIS-AZ NASAL SPRAY FOR TREATMENT OF MODERATE TO SEVERE ALLERGIC RHINITIS, IN INDIA* LAUNCHES RYALTRIS-AZ AT 175...
-
BRIEF-Glenmark Pharmaceuticals Says Unit To Commercialize Ryaltris Nasal Spray In Canada
March 22 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS :* GLENMARK PHARMACEUTICALS - UNIT TO COMMERCIALIZE RYALTRIS NASAL SPRAY IN CANADA...
-
BRIEF-Glenmark Pharma Gets Russian Marketing Approval For Ryaltris Nasal Spray
Feb 22 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS :* SWISS UNIT GOT MARKETING APPROVAL FROM MINISTRY OF HEALTH OF RUSSIAN FEDERATION FOR ITS RYALTRIS NASAL SPRAY* RYALTRIS EXPECTED...
-
Fitch Upgrades Jubilant Pharma to 'BB'; Outlook Stable, Off RWP
(The following statement was released by the rating agency) Fitch Ratings-Singapore-18 February 2021: Fitch Ratings has upgraded Singapore-based Jubilant Pharma Limited's (JPL) Long-Term...
-
BRIEF-Glenmark Receives ANDA Approval for Clindamycin Phosphate Gel
Feb 11 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS :* RECEIVES ANDA APPROVAL FOR CLINDAMYCIN PHOSPHATE GEL USP, 1%...
-
BRIEF-Glenmark Pharmaceuticals Gets ANDA Approval For Amphetamine Sulfate Tablets
Jan 28 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS :* RECEIVES ANDA APPROVAL FOR AMPHETAMINE SULFATE TABLETS USP, 5 MG AND 10 MG...
-
UPDATE 1-India's Dr.Reddy's ends study of COVID-19 drug Avigan in Kuwait
(Adds background on Avigan, context)BENGALURU, Jan 27 (Reuters) - Indian drugmaker Dr.Reddy's Laboratories REDY.NS said on Wednesday it had terminated its clinical study of Fujifilm...
-
BRIEF-Glenmark Pharma Gets Tentative U.S. FDA Approval For Axitinib Tablets
Dec 1 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS :* GOT TENTATIVE APPROVAL BY U.S. FDA FOR AXITINIB TABLETS, 1 MG AND 5 MG...
-
BRIEF-Glenmark Pharmaceuticals - S&P Global Ratings Affirms Long-Term Issuer Credit Rating Of Co
Nov 24 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS :* GLENMARK PHARMACEUTICALS LTD - S&P GLOBAL RATINGS AFFIRMS LONG-TERM ISSUER CREDIT RATING OF CO* GLENMARK PHARMACEUTICALS LTD -...
-
BRIEF-Glenmark Says Phase 3 Favipiravir Data For Covid-19 Shows Improvement In Time To Clinical Cure
Nov 23 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS :* DATA ON FAVIPIRAVIR AS TREATMENT FOR MILD TO MODERATE COVID-19 SHOWS IMPROVEMENT IN TIME TO CLINICAL CURE* FINDINGS WERE OBSERVED...
-
Sun Pharma’s Q2 Earnings: What Can You Expect?
By Aditya Raghunath Investing.com -- Sun Pharma (NS:SUN) is all set to announce its earnings for the second quarter of 2020 today. The stock is not expected to throw up any surprises....
-
BRIEF-Glenmark Pharmaceuticals Ltd - Gets ANDA Approval For Sirolimus Tablets, 0.5-2 MG
Oct 19 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS :* GLENMARK PHARMACEUTICALS LTD - GLENMARK PHARMACEUTICALS RECEIVES ANDA APPROVAL FOR SIROLIMUS TABLETS, 0.5 MG, 1 MG AND 2 MG...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
